DK3998285T3 - Bindingsmolekyler til cd38 og pd-l1 - Google Patents

Bindingsmolekyler til cd38 og pd-l1 Download PDF

Info

Publication number
DK3998285T3
DK3998285T3 DK21214273.1T DK21214273T DK3998285T3 DK 3998285 T3 DK3998285 T3 DK 3998285T3 DK 21214273 T DK21214273 T DK 21214273T DK 3998285 T3 DK3998285 T3 DK 3998285T3
Authority
DK
Denmark
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
DK21214273.1T
Other languages
English (en)
Inventor
Eugene Zhukovsky
Olivier Leger
Richard J Morse
Original Assignee
Biomunex Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomunex Pharmaceuticals filed Critical Biomunex Pharmaceuticals
Application granted granted Critical
Publication of DK3998285T3 publication Critical patent/DK3998285T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK21214273.1T 2016-03-25 2017-03-27 Bindingsmolekyler til cd38 og pd-l1 DK3998285T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305350 2016-03-25
EP17713672.8A EP3433273B1 (en) 2016-03-25 2017-03-27 Binding molecules to cd38 and pd-l1

Publications (1)

Publication Number Publication Date
DK3998285T3 true DK3998285T3 (da) 2025-04-14

Family

ID=55646510

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17713672.8T DK3433273T3 (da) 2016-03-25 2017-03-27 Binding af molekyler til cd38 og pd-l1
DK21214273.1T DK3998285T3 (da) 2016-03-25 2017-03-27 Bindingsmolekyler til cd38 og pd-l1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17713672.8T DK3433273T3 (da) 2016-03-25 2017-03-27 Binding af molekyler til cd38 og pd-l1

Country Status (16)

Country Link
US (2) US11505616B2 (da)
EP (2) EP3998285B1 (da)
JP (2) JP7529401B2 (da)
KR (1) KR102361412B1 (da)
CN (2) CN109476741B (da)
AU (1) AU2017236183B2 (da)
CA (1) CA3022143A1 (da)
DK (2) DK3433273T3 (da)
ES (2) ES3023551T3 (da)
FI (1) FI3998285T3 (da)
HU (2) HUE070697T2 (da)
PL (2) PL3998285T3 (da)
PT (2) PT3998285T (da)
RU (1) RU2764201C2 (da)
SG (1) SG11201808289SA (da)
WO (1) WO2017162890A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476741B (zh) 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
CN109563166B (zh) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
JP7612329B2 (ja) 2017-01-09 2025-01-14 ビオミューネクス・ファルマシューティカル 多重特異的抗体を調製するためのポリペプチドリンカー
CN120842423A (zh) * 2017-03-27 2025-10-28 拜奥穆尼克斯制药 稳定的多特异性抗体
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
WO2019137552A1 (en) * 2018-01-15 2019-07-18 I-Mab MODIFIED Cκ AND CH1 DOMAINS
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
SG11202103812RA (en) * 2018-10-17 2021-05-28 Immunome Inc Exosome-targeting bispecific antibodies
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
KR20210108421A (ko) 2018-12-24 2021-09-02 사노피 돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
US20240239912A1 (en) * 2020-04-10 2024-07-18 The Board Of Trustees Of The Leland Stanford Junior University Targeted reduction of activated immune cells
JP2022045530A (ja) * 2020-09-09 2022-03-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１標的化ｉｌ－２変異体免疫サイトカインとヒトｐｄ－ｌ１に対する抗体との併用療法
WO2022150787A2 (en) * 2021-01-11 2022-07-14 Adimab, Llc Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same
EP4538379A1 (en) 2022-06-10 2025-04-16 Fujifilm Diosynth Biotechnologies UK Limited Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, cho cells, and cell pool

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CN101289511A (zh) * 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US8263746B2 (en) * 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US10047163B2 (en) * 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
CN110627907B (zh) 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
CN109476741B (zh) * 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
CN109563166B (zh) 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
JP7612329B2 (ja) 2017-01-09 2025-01-14 ビオミューネクス・ファルマシューティカル 多重特異的抗体を調製するためのポリペプチドリンカー
CN120842423A (zh) 2017-03-27 2025-10-28 拜奥穆尼克斯制药 稳定的多特异性抗体
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
ES3023551T3 (en) 2025-06-02
CN116284428A (zh) 2023-06-23
SG11201808289SA (en) 2018-10-30
FI3998285T3 (fi) 2025-04-08
DK3433273T3 (da) 2022-02-14
RU2018137419A3 (da) 2020-08-17
RU2764201C2 (ru) 2022-01-14
US20230146591A1 (en) 2023-05-11
RU2018137419A (ru) 2020-04-27
CA3022143A1 (en) 2017-09-28
PL3433273T3 (pl) 2022-04-04
EP3433273B1 (en) 2021-12-29
KR20190016942A (ko) 2019-02-19
KR102361412B1 (ko) 2022-02-09
ES2906639T3 (es) 2022-04-19
AU2017236183A1 (en) 2018-11-15
WO2017162890A1 (en) 2017-09-28
JP2022116166A (ja) 2022-08-09
CN109476741A (zh) 2019-03-15
US11505616B2 (en) 2022-11-22
JP2019516396A (ja) 2019-06-20
HUE057657T2 (hu) 2022-06-28
AU2017236183B2 (en) 2024-03-07
PT3998285T (pt) 2025-04-14
EP3998285A1 (en) 2022-05-18
CN109476741B (zh) 2023-02-24
EP3433273A1 (en) 2019-01-30
US20200010559A1 (en) 2020-01-09
PL3998285T3 (pl) 2025-06-09
PT3433273T (pt) 2022-02-21
US12528877B2 (en) 2026-01-20
HUE070697T2 (hu) 2025-06-28
JP7529401B2 (ja) 2024-08-06
EP3998285B1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
DK3998285T3 (da) Bindingsmolekyler til cd38 og pd-l1
IL261942A (en) Bcma binding molecules and methods of use thereof
IL263730A (en) Binding molecules binding pd-l1 and lag-3
DK3328419T3 (da) Pd-1-bindingsmolekyler og fremgangsmåder til anvendelse deraf
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
IL256416B (en) Multispecific antigen-binding molecules and uses thereof
IL266464A (en) Binding of specific molecules to asct2 and their use
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3303265T3 (da) Sammensætning indeholdende n-(n-butyl)-thiophosphortriamid-additionsprodukter og reaktionsprodukter
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
GB201612520D0 (en) Binding molecules
DK3097122T3 (da) Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
IL262519A (en) Binding molecules specific for fcgamma riia and uses thereof
ZA201803841B (en) Binding molecules specific for asct2 and uses thereof
DK3105250T3 (da) Multispecifikke iga-bindingsmolekyler
IL261653A (en) Ilt7 binding molecules and methods of using the same
IL258956A (en) Compositions and methods for tumor transduction
DK3128997T3 (da) Bindingmolekyler specifikke for il-21 og anvendelser deraf
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf
DK3303384T3 (da) Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
EP3774922A4 (en) BINDING MOLECULES INVOLVING CELLS
DK3369208T3 (da) System og fremgangsmåde til aflytningssikret godkendelse og kryptering
DK3245204T3 (da) Små molekyler til behandling af primær cancer og cancermetastase